Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Overview of the management of epilepsy in adults

INTRODUCTION

The management of patients with epilepsy is focused on three main goals: controlling seizures, avoiding treatment side effects, and maintaining or restoring quality of life. Physicians should assist in empowering patients with epilepsy to lead lifestyles consistent with their capabilities [1,2].

The optimal treatment plan is derived following an accurate diagnosis of the patient's seizure type(s), an objective measure of the intensity and frequency of the seizures, awareness of medication side effects, and an evaluation of disease-related psychosocial problems. A working knowledge of available antiepileptic drugs (AEDs), including their mechanisms of action, pharmacokinetics, drug-drug interactions, and adverse effects is essential.

It is usually appropriate to refer the patient to a neurologist, when establishing a diagnosis and formulating a course of treatment. Referral to an epilepsy specialist may be necessary if there is doubt about the diagnosis and/or if the patient continues to have seizures.

The overall approach to management of a patient with seizures is reviewed here. Evaluation of the patient who has had a first seizure and the pharmacology of specific AEDs are discussed separately. (See "Evaluation of the first seizure in adults" and "Initial treatment of epilepsy in adults" and "Overview of antiepileptic drugs".)

CLASSIFICATION

The first step in designing a treatment plan is to classify the patient's seizure type(s) using the framework of the International League Against Epilepsy (table 1) [3,4]. Seizure types and epilepsy syndromes are classified primarily upon clinical grounds, assisted by laboratory, neurophysiologic, and radiographic studies. Seizure type has important implications in the choice of antiepileptic drugs (AEDs). Accurate classification requires a full history from the patient and reports from observers who have witnessed actual seizures.

                                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Oct 14, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Schachter SC. Advances in the assessment of refractory epilepsy. Epilepsia 1993; 34 Suppl 5:S24.
  2. Schachter SC. Update in the treatment of epilepsy. Compr Ther 1995; 21:473.
  3. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.
  4. Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2011; 76:94.
  5. Schachter SC. Brainstorms: Epilepsy in Our Words, Raven Press, New York 1993.
  6. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.
  7. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.
  8. Petrovski S, Szoeke CE, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010; 75:1015.
  9. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.
  10. Bonnett LJ, Tudur Smith C, Donegan S, Marson AG. Treatment outcome after failure of a first antiepileptic drug. Neurology 2014; 83:552.
  11. Lüders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.
  12. Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51:797.
  13. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57:1.
  14. Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42:1387.
  15. Haag A, Strzelczyk A, Bauer S, et al. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients. Epilepsy Behav 2010; 19:618.
  16. Costa J, Fareleira F, Ascenção R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011; 52:1280.
  17. Zaccara G, Almas M, Pitman V, et al. Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial. Epilepsia 2014; 55:1048.
  18. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41:1364.
  19. Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006; 66:1817.
  20. Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 2007; 48:412.
  21. Margolis JM, Chu BC, Wang ZJ, et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol 2014; 71:985.
  22. Moeller JJ, Rahey SR, Sadler RM. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia 2009; 50:475.
  23. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26:423.
  24. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40:1141.
  25. Poolos NP, Warner LN, Humphreys SZ, Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012; 78:62.
  26. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375.
  27. Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62:382.
  28. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70:54.
  29. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4344b1_10_03_Trileptal%20Update.pdf.
  30. Bell GS, Gaitatzis A, Bell CL, et al. Suicide in people with epilepsy: how great is the risk? Epilepsia 2009; 50:1933.
  31. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010; 75:335.
  32. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363:542.
  33. Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009; 50:978.
  34. Roeder R, Roeder K, Asano E, Chugani HT. Depression and mental health help-seeking behaviors in a predominantly African American population of children and adolescents with epilepsy. Epilepsia 2009; 50:1943.
  35. Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia 2013; 54:199.
  36. Shneker BF, Cios JS, Elliott JO. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009; 72:987.
  37. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
  38. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.
  39. Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010; 19:405.
  40. Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011; 77:2025.
  41. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.
  42. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm.
  43. Linnebank M, Moskau S, Semmler A, et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol 2011; 69:352.
  44. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.
  45. Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328:1273.
  46. National Institute for Clinical Excellence. Newer drugs for epilepsy in adults, full guidance. Technology Appraisal Guidance 76, March 2004. www.nice.org.uk/TA076guidance (Accessed on March 3, 2005).
  47. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.
  48. Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71:1572.
  49. Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72:419.
  50. Kaiboriboon K, Guevara M, Alldredge BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009; 50:1927.
  51. Fisher RS. Tracking epilepsy with an electronic diary. Acta Paediatr 2010; 99:516.
  52. My Epilepsy Diary. Available at: http://www.epilepsy.com/seizurediary (Accessed on June 04, 2010).
  53. Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology 2007; 69:1905.
  54. Dionisio J, Tatum WO 4th. Triggers and techniques in termination of partial seizures. Epilepsy Behav 2010; 17:210.
  55. Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007; 64:1595.
  56. Berg MJ, Gross RA, Haskins LS, et al. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; 13:693.
  57. McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav 2009; 14:113.
  58. Papsdorf TB, Ablah E, Ram S, et al. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009; 14:150.
  59. Chaluvadi S, Chiang S, Tran L, et al. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia 2011; 52:810.
  60. Krauss GL, Caffo B, Chang YT, et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 2011; 70:221.
  61. Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007; 68:1249.
  62. Berg MJ. What's the problem with generic antiepileptic drugs?: a call to action. Neurology 2007; 68:1245.
  63. Krämer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007; 11:46.
  64. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48:1825.
  65. Nielsen KA, Dahl M, Tømmerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13:127.
  66. Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50:493.
  67. Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav 2009; 15:481.
  68. Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009; 29:769.
  69. Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH. Clinical outcomes associated with brand-to-generic phenytoin interchange. Ann Pharmacother 2012; 46:650.
  70. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70:2179.
  71. Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009; 72:2122.
  72. Labiner DM, Paradis PE, Manjunath R, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010; 74:1566.
  73. Helmers SL, Paradis PE, Manjunath R, et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 2010; 18:437.
  74. Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525.
  75. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010; 70:605.
  76. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42:1266.
  77. Hauser WA, Ng SK, Brust JC. Alcohol, seizures, and epilepsy. Epilepsia 1988; 29 Suppl 2:S66.
  78. Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009; 14:324.
  79. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009; 14:372.
  80. Brown I, Sheeran P, Reuber M. Enhancing antiepileptic drug adherence: a randomized controlled trial. Epilepsy Behav 2009; 16:634.
  81. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069.
  82. Labiner DM, Bagic AI, Herman ST, et al. Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines. Epilepsia 2010; 51:2322.
  83. Tyagi A, Delanty N. Herbal remedies, dietary supplements, and seizures. Epilepsia 2003; 44:228.
  84. Lee SW, Chung SS. A review of the effects of vitamins and other dietary supplements on seizure activity. Epilepsy Behav 2010; 18:139.
  85. Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev 2012; 6:CD006967.
  86. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012; 6:CD009270.
  87. Pearl PL, Drillings IM, Conry JA. Herbs in epilepsy: evidence for efficacy, toxicity, and interactions. Semin Pediatr Neurol 2011; 18:203.
  88. Stavem K, Kloster R, Røssberg E, et al. Acupuncture in intractable epilepsy: lack of effect on health-related quality of life. Seizure 2000; 9:422.
  89. Cheuk DK, Wong V. Acupuncture for epilepsy. Cochrane Database Syst Rev 2006; :CD005062.
  90. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.
  91. Harden CL, Hopp J, Ting TY, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1229.
  92. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1237.
  93. Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1247.
  94. Beghi E, Cornaggia C, RESt-1 Group. Morbidity and accidents in patients with epilepsy: results of a European cohort study. Epilepsia 2002; 43:1076.
  95. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519.
  96. Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66:S37.
  97. Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2011; 52:243.
  98. Pennell PB, Gidal BE, Sabers A, et al. Pharmacology of antiepileptic drugs during pregnancy and lactation. Epilepsy Behav 2007; 11:263.
  99. Morrell MJ, Flynn KL, Seale CG, et al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001; 6:771.
  100. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.
  101. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).
  102. Thorneycroft I, Klein P, Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav 2006; 9:31.
  103. O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47:1419.
  104. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005; 31:139.
  105. Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28:78.
  106. Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009; 116:758.
  107. http://www.fsrh.org/pdfs/CEUstatementLevonelle1500.pdf.
  108. Sukumaran SC, Sarma PS, Thomas SV. Polytherapy increases the risk of infertility in women with epilepsy. Neurology 2010; 75:1351.
  109. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352:1970.
  110. Olafsson E, Hauser WA, Gudmundsson G. Fertility in patients with epilepsy: a population-based study. Neurology 1998; 51:71.
  111. Pack AM. Infertility in women with epilepsy: what's the risk and why? Neurology 2010; 75:1316.
  112. Verrotti A, D'Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199.
  113. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.
  114. Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57:1617.
  115. Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol 2002; 59:195.
  116. Sung CY, Chu NS. Epileptic seizures in thrombotic stroke. J Neurol 1990; 237:166.
  117. Graham NS, Crichton S, Koutroumanidis M, et al. Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register. Stroke 2013; 44:605.
  118. Lossius MI, Rønning OM, Slapø GD, et al. Poststroke epilepsy: occurrence and predictors--a long-term prospective controlled study (Akershus Stroke Study). Epilepsia 2005; 46:1246.
  119. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35:1769.
  120. Heuts-van Raak L, Lodder J, Kessels F. Late seizures following a first symptomatic brain infarct are related to large infarcts involving the posterior area around the lateral sulcus. Seizure 1996; 5:185.
  121. Cordonnier C, Hénon H, Derambure P, et al. Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. J Neurol Neurosurg Psychiatry 2005; 76:1649.
  122. Velioğlu SK, Ozmenoğlu M, Boz C, Alioğlu Z. Status epilepticus after stroke. Stroke 2001; 32:1169.
  123. Gupta SR, Naheedy MH, Elias D, Rubino FA. Postinfarction seizures. A clinical study. Stroke 1988; 19:1477.
  124. Gilad R, Sadeh M, Rapoport A, et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007; 30:189.
  125. Alvarez-Sabín J, Montaner J, Padró L, et al. Gabapentin in late-onset poststroke seizures. Neurology 2002; 59:1991.
  126. Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.
  127. Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38:31.
  128. Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 2010; 51:2241.
  129. Mu J, Liu L, Zhang Q, et al. Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology 2011; 77:132.
  130. Trinka E, Bauer G, Oberaigner W, et al. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia 2013; 54:495.
  131. Callaghan B, Choi H, Schlesinger M, et al. Increased mortality persists in an adult drug-resistant epilepsy prevalence cohort. J Neurol Neurosurg Psychiatry 2014; 85:1084.
  132. Benn EK, Hauser WA, Shih T, et al. Underlying cause of death in incident unprovoked seizures in the urban community of Northern Manhattan, New York City. Epilepsia 2009; 50:2296.
  133. Day SM, Wu YW, Strauss DJ, et al. Causes of death in remote symptomatic epilepsy. Neurology 2005; 65:216.
  134. Bell GS, Gaitatzis A, Bell CL, et al. Drowning in people with epilepsy: how great is the risk? Neurology 2008; 71:578.
  135. Fazel S, Wolf A, Långström N, et al. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet 2013; 382:1646.
  136. St Germaine-Smith C, Liu M, Quan H, et al. Development of an epilepsy-specific risk adjustment comorbidity index. Epilepsia 2011; 52:2161.
  137. Annegers JF, Coan SP. SUDEP: overview of definitions and review of incidence data. Seizure 1999; 8:347.
  138. Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 1989; 26:195.
  139. Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 1999; 353:888.
  140. Walczak TS, Leppik IE, D'Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001; 56:519.
  141. Annegers JF, Melton LJ 3rd, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989; 30:348.
  142. Kirby S, Sadler RM. Injury and death as a result of seizures. Epilepsia 1995; 36:25.
  143. Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99:269.
  144. Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002; 43:768.
  145. Friedman DE, Tobias RS, Akman CI, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: a 2-year longitudinal study. Epilepsy Behav 2010; 19:400.
  146. Kwon CS, Liu M, Quan H, et al. The incidence of injuries in persons with and without epilepsy--a population-based study. Epilepsia 2010; 51:2247.
  147. Lawn ND, Bamlet WR, Radhakrishnan K, et al. Injuries due to seizures in persons with epilepsy: a population-based study. Neurology 2004; 63:1565.
  148. Bowman SM, Aitken ME, Sharp GB. Disparities in injury death location for people with epilepsy/seizures. Epilepsy Behav 2010; 17:369.
  149. Kwon C, Liu M, Quan H, et al. Motor vehicle accidents, suicides, and assaults in epilepsy: a population-based study. Neurology 2011; 76:801.
  150. Shackleton DP, Kasteleijn-Nolst Trenité DG, de Craen AJ, et al. Living with epilepsy: long-term prognosis and psychosocial outcomes. Neurology 2003; 61:64.
  151. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012; 380:1180.
  152. Strine TW, Kobau R, Chapman DP, et al. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 2005; 46:1133.
  153. Schachter SC, Shafer PO, Murphy W. The personal impact of epilepsy: Correlations with seizure frequency, employment, cost of medical care, and satisfaction with physician care. J Epilepsy 1993; 6:224.
  154. Holland P, Lane S, Whitehead M, et al. Labor market participation following onset of seizures and early epilepsy: Findings from a UK cohort. Epilepsia 2009; 50:1030.
  155. Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 2011; 52:949.
  156. Gauffin H, Landtblom AM, Räty L. Self-esteem and sense of coherence in young people with uncomplicated epilepsy: a 5-year follow-up. Epilepsy Behav 2010; 17:520.
  157. Hinnell C, Williams J, Metcalfe A, et al. Health status and health-related behaviors in epilepsy compared to other chronic conditions--a national population-based study. Epilepsia 2010; 51:853.
  158. Samokhvalov AV, Irving H, Mohapatra S, Rehm J. Alcohol consumption, unprovoked seizures, and epilepsy: a systematic review and meta-analysis. Epilepsia 2010; 51:1177.
  159. Devinsky O. Clinical uses of the quality-of-life in epilepsy inventory. Epilepsia 1993; 34 Suppl 4:S39.
  160. Ramaratnam S, Baker GA, Goldstein L. Psychological treatments for epilepsy. Cochrane Database Syst Rev 2001; :CD002029.
  161. Layne Moore J, Elliott JO, Lu B, et al. Serious psychological distress among persons with epilepsy based on the 2005 California Health Interview Survey. Epilepsia 2009; 50:1077.
  162. Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia 2009; 50:1051.
  163. Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48:2336.
  164. Seminario NA, Farias ST, Jorgensen J, et al. Determination of prevalence of depression in an epilepsy clinic using a brief DSM-IV-based self-report questionnaire. Epilepsy Behav 2009; 15:362.
  165. Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013; 80:590.
  166. Rai D, Kerr MP, McManus S, et al. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia 2012; 53:1095.
  167. Reisinger EL, DiIorio C. Individual, seizure-related, and psychosocial predictors of depressive symptoms among people with epilepsy over six months. Epilepsy Behav 2009; 15:196.
  168. Adelöw C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012; 78:396.
  169. Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012; 72:184.
  170. Szaflarski M, Meckler JM, Privitera MD, Szaflarski JP. Quality of life in medication-resistant epilepsy: the effects of patient's age, age at seizure onset, and disease duration. Epilepsy Behav 2006; 8:547.
  171. Kwan P, Yu E, Leung H, et al. Association of subjective anxiety, depression, and sleep disturbance with quality-of-life ratings in adults with epilepsy. Epilepsia 2009; 50:1059.
  172. Park SP, Song HS, Hwang YH, et al. Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy. Epilepsy Behav 2010; 18:455.
  173. Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011; 52:2168.
  174. Kanner AM, Barry JJ, Gilliam F, et al. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia 2012; 53:1104.
  175. Stefanello S, Marín-Léon L, Fernandes PT, et al. Suicidal thoughts in epilepsy: a community-based study in Brazil. Epilepsy Behav 2010; 17:483.
  176. Hesdorffer DC, French JA, Posner K, et al. Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials. Epilepsia 2013; 54:879.
  177. Christensen J, Vestergaard M, Mortensen PB, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007; 6:693.
  178. Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.
  179. Rathore JS, Jehi LE, Fan Y, et al. Validation of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy. Epilepsy Behav 2014; 37:215.
  180. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001; 357:216.
  181. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002; 58:S21.
  182. Aldenkamp AP, Bodde N. Behaviour, cognition and epilepsy. Acta Neurol Scand Suppl 2005; 182:19.
  183. Taylor J, Kolamunnage-Dona R, Marson AG, et al. Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia 2010; 51:48.
  184. Hermann BP, Seidenberg M, Dow C, et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol 2006; 60:80.
  185. Baker GA, Taylor J, Aldenkamp AP, SANAD group. Newly diagnosed epilepsy: cognitive outcome after 12 months. Epilepsia 2011; 52:1084.
  186. Sander JW. Comorbidity and premature mortality in epilepsy. Lancet 2013; 382:1618.
  187. Ottman R, Lipton RB, Ettinger AB, et al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia 2011; 52:308.
  188. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2013; 62.
  189. Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012; 53:1282.
  190. Vendrame M, Jackson S, Syed S, et al. Central sleep apnea and complex sleep apnea in patients with epilepsy. Sleep Breath 2014; 18:119.
  191. Phillips MC, Costello CA, White EJ, et al. Routine polysomnography in an epilepsy monitoring unit. Epilepsy Res 2013; 105:401.
  192. Pornsriniyom D, Shinlapawittayatorn K, Fong J, et al. Continuous positive airway pressure therapy for obstructive sleep apnea reduces interictal epileptiform discharges in adults with epilepsy. Epilepsy Behav 2014; 37:171.
  193. Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 2008; 49:455.
  194. Randomised study of antiepileptic drug withdrawal in patients in remission. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Lancet 1991; 337:1175.
  195. Specchio LM, Tramacere L, La Neve A, Beghi E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J Neurol Neurosurg Psychiatry 2002; 72:22.
  196. Britton JW. Antiepileptic drug withdrawal: literature review. Mayo Clin Proc 2002; 77:1378.
  197. Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. N Engl J Med 1988; 318:942.
  198. Cardoso TA, Coan AC, Kobayashi E, et al. Hippocampal abnormalities and seizure recurrence after antiepileptic drug withdrawal. Neurology 2006; 67:134.
  199. Aktekin B, Dogan EA, Oguz Y, Senol Y. Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Behav 2006; 8:616.
  200. Koepp MJ, Farrell F, Collins J, Smith S. The prognostic value of long-term ambulatory electroencephalography in antiepileptic drug reduction in adults with learning disability and epilepsy in long-term remission. Epilepsy Behav 2008; 13:474.
  201. Ranganathan LN, Ramaratnam S. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev 2006; :CD005003.
  202. Azar NJ, Wright AT, Wang L, et al. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal. Neurology 2008; 70:2187.